Prova Storytel gratis i 30 dagar Ett universum fyllt av ljudböcker, klicka här för att komma igång

The Readout Loud

En podcast av: STAT

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Our American listeners can also listen to The Readout Loud at our American site

350 Avsnitt

346: Zealand's obesity strategy and Immunovant's curious development plan
Publicerades 2025-03-20

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
Publicerades 2025-03-13
344: Trump's FDA commissioner nominee takes the hot seat
Publicerades 2025-03-06
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Publicerades 2025-02-27
342: FDA cuts, zombie biotechs, and too much weight loss?
Publicerades 2025-02-20
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Publicerades 2025-02-13
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
Publicerades 2025-02-06
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Publicerades 2025-01-30
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
Publicerades 2025-01-23
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
Publicerades 2025-01-15
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
Publicerades 2025-01-09
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
Publicerades 2024-12-19
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Publicerades 2024-12-12
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Publicerades 2024-12-05
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Publicerades 2024-11-21
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Publicerades 2024-11-14
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Publicerades 2024-11-07
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Publicerades 2024-10-31
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Publicerades 2024-10-24
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Publicerades 2024-10-17

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

350 Avsnitt

346: Zealand's obesity strategy and Immunovant's curious development plan

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

344: Trump's FDA commissioner nominee takes the hot seat

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

342: FDA cuts, zombie biotechs, and too much weight loss?

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

338: Chinese biotechs, a WHO departure, and post-JPM thoughts

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

333: An H5N1 bird flu update and talent scarcity in the radiopharma field

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights